Increased levels of low-density lipoprotein cholesterol (LDL-C) is one of the key risk factors for cardiovascular disease , taking the first place in the structure of adult mortality in Russia . According to Russian and International recommendations [3,4], only about one-third of patients who were treated with statin therapy alone achieved a LDL-C goal. In such cases, it is recommended to use statin drugs in combination with other lipid-lowering agents, primarily with ezetimibe, a cholesterol absorption inhibitor, that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. Ezetimibe-statin combination therapy or ezetimibe monotherapy in addition to the diet is associated with a lower risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina or if revascularization is necessary) in patients with coronary heart disease (CHD) .
"The launch of a new product on the market expands the cardiology portfolio of Egis and embodies the strategy of an integrated approach to the prevention of cardiovascular diseases. The combination therapy of ezetimibe with statin helps to improve the quality of life of patients with hypercholesterolemia, as well as reduce the risk of cardiovascular events in patients with coronary heart disease or chronic kidney disease. Moreover, affordable of the product and a single dose per day can contribute to adherence to long-term therapy and to increase the frequency of achievement of target LDL-C level," says Olga Gultikova, Medical Director of EGIS-RUS LLC.